Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$1.85 USD
+0.08 (4.52%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRCA 1.85 +0.08(4.52%)
Will VRCA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Other News for VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Wall Street Breakfast: The Week Ahead
Catalyst Watch: August Jobs Report, Intel event, Broadcom earnings, and Costco sales
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Verrica Pharmaceuticals CCO Joe Bonaccorso Resigns, Assumes Consulting Role